[177Lu-DOTAGA.Glu 的有效性和安全性 (FAPi) 治疗瘤患者
Sanjana Ballal1, Mohammad Sakir1, Kunal R Chandekar1
1Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
概括
这项研究发现[177Lu]Lu-DOTAGA.Glu. 在肉瘤患者中,FAPi2治疗显示出抗瘤活性. 虽然需要进一步的研究,但治疗耐受性良好,一些患者实现了疾病控制.
科学领域:
- 核医学
- 癌症学
- 放射性药物治疗
背景情况:
- 瘤是一种罕见的癌症,治疗选择有限.
- 纤维细胞激活蛋白 (FAP) 是癌症治疗的一个有希望的点.
研究的目的:
- 评估[177Lu]Lu-DOTAGA的疗效和安全性. 在患有肉瘤的患者中进行 (FAPi) 2治疗.
- 评估疾病控制率,无进展存活率和整体存活率.
主要方法:
- 对10名用[177Lu]Lu-DOTAGA.Glu治疗的癌症患者进行了回顾性分析. (FAPi) 的一个.
- 在3个周期中累计活动的中位数为17.5GBq.
- 使用 PERCIST 和 RECIST 1.1 标准进行反应评估.
主要成果:
- [177Lu]Lu-DOTAGA.Glu. 这是一个很好的方法. (FAPi) 2的耐受性一般很好.
- 疾病控制率为50% (PERCIST) 和22.3% (RECIST).
- 中位数无进展生存时间为5个月;中位数整体生存时间为8个月.
结论:
- [177Lu]Lu-DOTAGA.Glu. 这是一个很好的方法. (FAPi) 2在肉瘤患者中表现出临床抗瘤活性.
- 这种疗法具有可控的安全性.
- 需要对更大群体和组合疗法进行进一步的研究.
更多相关视频
08:55A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
18.0K
10:33Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
Published on: April 25, 2025
371
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
721
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
721
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
